[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,109,560
  • Shares Outstanding, K 128,475
  • Annual Sales, $ 727,330 K
  • Annual Income, $ -108,030 K
  • EBIT $ -68 M
  • EBITDA $ 1 M
  • 60-Month Beta 1.74
  • Price/Sales 2.92
  • Price/Cash Flow 49.34
  • Price/Book 2.70

Options Overview Details

View History
  • Implied Volatility 56.76% (-4.58%)
  • Historical Volatility 57.98%
  • IV Percentile 6%
  • IV Rank 5.59%
  • IV High 315.47% on 03/13/26
  • IV Low 41.44% on 08/15/25
  • Expected Move (DTE 8) 0.98 (5.96%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 27
  • Volume Avg (30-Day) 266
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 15,496
  • Open Int (30-Day) 13,364
  • Expected Range 15.41 to 17.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 2
  • High Estimate $0.01
  • Low Estimate $-0.03
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) +80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.05 +25.59%
on 07/28/26
16.92 -3.13%
on 08/10/26
+2.28 (+16.16%)
since 07/13/26
3-Month
8.19 +100.00%
on 05/14/26
16.92 -3.13%
on 08/10/26
+8.13 (+98.43%)
since 05/13/26
52-Week
5.94 +175.93%
on 08/21/25
16.92 -3.13%
on 08/10/26
+10.15 (+162.66%)
since 08/13/25

Most Recent Stories

More News
3 Stocks Under $50 with Open Questions

3 Stocks Under $50 with Open Questions

OXM : 36.31 (+0.81%)
HAYW : 15.29 (-0.07%)
NEO : 16.39 (-0.18%)
3 Healthcare Stocks with Questionable Fundamentals

3 Healthcare Stocks with Questionable Fundamentals

NEO : 16.39 (-0.18%)
AORT : 28.41 (-0.80%)
OCUL : 10.10 (-1.27%)
Why NeoGenomics (NEO) Stock Is Up Today

Why NeoGenomics (NEO) Stock Is Up Today

NEO : 16.39 (-0.18%)
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

DKNG : 25.42 (-0.35%)
CCOI : 10.35 (+0.98%)
NEO : 16.39 (-0.18%)
NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue

NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue

NEO : 16.39 (-0.18%)
NeoGenomics: Q2 Earnings Snapshot

NeoGenomics: Q2 Earnings Snapshot

NEO : 16.39 (-0.18%)
NeoGenomics Reports Second Quarter 2026 Results

Total revenue increased 11% YoY to $202 million Clinical services revenue grew 14%, with NGS revenue growth of 26% Company raises full-year...

NEO : 16.39 (-0.18%)
NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For

NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For

NEO : 16.39 (-0.18%)
1 Momentum Stock with Solid Fundamentals and 2 We Avoid

1 Momentum Stock with Solid Fundamentals and 2 We Avoid

NEO : 16.39 (-0.18%)
SIRI : 27.99 (-1.58%)
TXRH : 207.01 (-3.39%)
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement...

NEO : 16.39 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

3rd Resistance Point 16.93
2nd Resistance Point 16.80
1st Resistance Point 16.59
Last Price 16.39
1st Support Level 16.25
2nd Support Level 16.12
3rd Support Level 15.91

See More

52-Week High 16.92
Last Price 16.39
Fibonacci 61.8% 12.73
Fibonacci 50% 11.43
Fibonacci 38.2% 10.13
52-Week Low 5.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.